Yungjin files 'KT&G101’ application for marketing approval with KFDA
Published: 2011-12-22 06:56:00
Updated: 2011-12-22 06:56:00
Biopid Co., a local biopharmaceutical company, said yesterday that its partner, Yungjin Pharma, has filed a marketing application for a new drug 'KT&G101’ for treatment of atopic dermatitis with the Korea Food and Drug Administration.
“KT&G101 possesses anti-inflammatory and related antinocice...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
